摘要
目的:分析高孕激素超促排卵方案中基础LH水平对PCOS患者IVFICSI治疗结局的影响。方法:回顾性分析海南医学院第二附属医院200例PCOS患者根据不同的LH水平随机分为A、B、C三组,三组均采用促性腺激素(Gn)联合安宫黄体酮(MPA)的高孕激素超促排卵方案治疗,其中A、B、C三组的LH水平分别为0 IU～5IU/L、5 IU～10IU/L和> 10IU/L。分析比较三组患者在治疗结局的差异。结果:三组患者在年龄、月经周期、不孕年限、BMI、既往失败次数、基础卵泡数和不孕因素(包含合并输卵管和男方因素)差异无统计学意义(P> 0. 05);基础FSH、LH和E2指标差异具有统计学意义(P <0. 05)。Gn用量、Gn用药天数、正常受精卵数、优质胚胎数、有效胚胎数和周期取消率变化均不明显,差异无统计学意义(P> 0. 05);获卵数、成熟卵数和成熟卵率变化明显,差异具有统计学意义(P <0. 05)。A、B、C三组患者的临床妊娠率分别为59. 2%、68. 9%和62. 5%,差异无统计学意义(P> 0. 05)。早期流产率、继续妊娠率均无明显变化,差异无统计学意义(P> 0. 05)。结论:高孕激素超促排卵方案在对PCOS患者进行IVFICSI治疗时,能够有效预防自发性LH峰发生,并且可促进卵组获得具有发育潜能的胚胎,在临床中值得推广应用。
Objective:To study the effect of the basic LH level in the high progesterone ovulation program on the outcome of IVFICSI treatment for PCOS patients.Methods:200 PCOS patients that received high progesterone superovulation scheme of gonadotropin(Gn)combined with progesterone(MPA)were divided into group A,B and C.The LH level of group A,B and C was 0-5IU/L,5-10IU/L and>10IU/L respectively.The differences in treatment outcomes were compared between the three groups.Results:There was no statistically significant difference in age,menstrual cycle,infertile years,BMI,number of times of previous failure,basal follicles and infertility factors(including tubal and male factors(P>0.05).Differences in basic FSH,LH and E2 indexes were statistically significant(P<0.05)Differences in the Gn dosage,number of days of Gn administration,number of normal fertilized eggs,number of high quality embryo,number of effective embryo and cycle cancellation rate were not statistically significant(P>0.05).Differences in the number of eggs obtained,the number of mature eggs and rate of mature eggs were statistically significant(P<0.05).The clinical pregnancy rate of group A,B and C was 59.2%,68.9%and 62.5%respectively(P>0.05).There was no significant change in early abortion rate and continuing pregnancy rate(P>0.05).Conclusions:High progesterone superovulation scheme can prevent spontaneous LH peaks and promote the developmental potential of embryos in IVFICSI treatment for PCOS patients,worthy of clinical promotion.
作者
李浩僡
郝佳渊
廖源
李娟
LI Haohui;HAO Jiayuan;LIAO Yuan;LI Juan(Department of Reproductive Medicine,The Second Hospital Affiliated to Hainan Medical University,Haikou 570311,Hainan,China)
出处
《中国性科学》
2018年第11期92-95,共4页
Chinese Journal of Human Sexuality
基金
2017年海南省重大科技计划项目(ZDKJ2017007)
